What is Invitae?
Invitae operates as a specialized medical genetics company, bridging the gap between complex DNA analysis and actionable clinical insights. By processing samples from in-home test kits and clinical referrals, the firm provides comprehensive genetic testing services that empower clinicians and patients to make informed healthcare decisions. Its market position is defined by its ability to translate patient-specific genetic variations into structured, readable reports, thereby facilitating personalized medicine at scale.
The company's platform is designed to address the growing demand for accessible genomic data, positioning it as a vital component of the modern diagnostic ecosystem. By focusing on the intersection of technology and clinical utility, Invitae continues to refine its processes for analyzing genetic information, ensuring that its diagnostic outputs remain at the forefront of the industry.
How much funding has Invitae raised?
Invitae has raised a total of $1.2B across 11 funding rounds:
Series F
$120M
Stock Offering
$116.8M
Share Placement
$73.5M
Debt
$40M
Stock Offering
$53.5M
Stock Offering
$196.7M
Debt
$291.2M
Stock Offering
$184M
Share Placement
$30M
Series F (2014): $120M supported by OrbiMed, Genomic Health, Deerfield, Randy Scott, Wellington Management, Decheng Capital, Perceptive Advisors, The Broe Group, Thomas McNerney & Partners, Genesys Capital, Casdin Capital, Redmile Group, and Rock Springs Capital
Stock Issuance/Offering (2015): $116.8M featuring Undisclosed
Share Placement (2017): $73.5M backed by Undisclosed
Debt (2018): $40M with participation from Oxford Finance
Stock Issuance/Offering (2018): $53.5M led by Undisclosed
Stock Issuance/Offering (2019): $196.7M supported by Undisclosed
Debt (2019): $291.2M featuring Undisclosed
Stock Issuance/Offering (2020): $184M backed by Undisclosed
Share Placement (2023): $30M, investors not publicly disclosed
Key Investors in Invitae
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, diagnostics, and medical devices to support innovation at various stages of development.
Casdin Capital
Casdin Capital brings deep expertise to the life science sector, specifically focusing on diagnostics and molecular information portfolios to finance the next generation of healthcare innovation.
Wellington Management
Wellington Management is a global, independent investment firm providing institutional clients with tailored financial solutions across equities and alternative strategies.
What's next for Invitae?
Looking ahead, the strategic deployment of $30M is expected to bolster Invitae's operational capacity and support the continued expansion of its genomic intelligence platform. As the company moves deeper into its lifecycle, the focus will likely shift toward enhancing the clinical integration of its test reports and optimizing the efficiency of its DNA processing workflows. The firm remains well-positioned to leverage its established network of healthcare providers to drive further adoption of its diagnostic services.
Furthermore, the company's history of securing diverse capital—ranging from venture-backed rounds to public offerings—suggests a robust financial foundation capable of supporting long-term research and development initiatives. Future growth will likely be characterized by a continued emphasis on scaling its diagnostic capabilities and maintaining its competitive edge in the rapidly evolving field of molecular diagnostics.
